Table 1. Patient characteristics of esophagitis grade 0–1 and grade ≥2.
| Characteristic | Grade 0–1 (n=59) | Grade ≥2 (n=41) | χ2 |
|---|---|---|---|
| Age | 0.591 | ||
| <65 | 32 (54.2) | 20 (48.8) | |
| ≥65 | 27 (45.8) | 21 (51.2) | |
| Sex | 0.313 | ||
| Male | 53 (89.8) | 34 (82.9) | |
| Female | 6 (10.2) | 7 (17.0) | |
| Tumor location | 0.028* | ||
| Cervical | 0 (0) | 4 (9.8) | |
| Upper | 13 (22.0) | 10 (24.4) | |
| Middle | 33 (56.0) | 14 (34.1) | |
| Lower | 13 (22.0) | 13 (31.7) | |
| Clinical stage | 0.359 | ||
| I–II | 13 (22.0) | 6 (14.6) | |
| III–IV | 46 (78.0) | 35 (85.4) | |
| Treatment | 0.058 | ||
| Radiotherapy | 14 (23.7) | 10 (24.4) | |
| Chemoradiotherapy | 10 (16.9) | 15 (36.6) | |
| Preoperative chemoradiotherapy | 35 (59.3) | 16 (39.0) | |
| Dose (Gy) | 0.013* | ||
| ≤40 | 26 (44.1) | 12 (29.3) | |
| >40 | 33 (55.9) | 29 (70.7) | |
| GTV (cm3) | 0.134 | ||
| <50 | 26 (44.1) | 12 (29.3) | |
| ≥50 | 33 (55.9) | 29 (70.7) | |
| PTV (cm3) | 0.047* | ||
| <495 | 29 (49.2) | 12 (29.3) | |
| ≥495 | 30 (50.8) | 29 (70.7) | |
| BMI | 0.239 | ||
| Underweight | 12 (20.3) | 5 (12.2) | |
| Normal | 35 (59.3) | 31 (75.6) | |
| Overweight/obesity | 12 (20.3) | 5 (12.2) | |
| PG-SGA | 0.001* | ||
| B (<9) | 41 (69.5) | 15 (36.6) | |
| C (≥9) | 18 (30.5) | 26 (63.4) | |
| WL | 0.017* | ||
| <10% | 40 (67.8) | 18 (43.9) | |
| ≥10% | 19 (32.2) | 23 (56.1) | |
| ALB (g/L) | 0.041* | ||
| ≥35 | 47 (79.7) | 25 (61.0) | |
| <35 | 12 (20.3) | 16 (39.0) | |
| HB (g/L) | 0.756 | ||
| >120 | 49 (83.1) | 35 (85.4) | |
| ≤120 | 10 (16.9) | 6 (14.6) | |
| CRP (mg/L) | 0.437 | ||
| <10 | 32 (54.2) | 19 (46.3) | |
| ≥10 | 27 (45.8) | 22 (53.7) | |
| ADS | 0.437 | ||
| ≤1 | 32 (54.2) | 19 (46.3) | |
| >1 | 27 (45.8) | 22 (53.7) | |
| GPS | 0.185 | ||
| 0 | 28 (47.5) | 14 (34.1) | |
| 1/2 | 31 (52.5) | 27 (65.9) |
*, statistical significance at P<0.05. GTV, gross tumor volume; PTV, planning tumor volume; BMI, body mass index; PG-SGA, Patient-Generated Subjective Global Assessment; ALB, albumin; HB, hemoglobin; CRP, C-reactive protein; ADS, Atkinson dysphagia score; GPS, Glasgow prognostic score.